Sunflower Pharmaceutical (002737.SZ) traded flat 0 % during a 24 hours period ending at 04:47 PM Central Europe on Monday 26th. One Sunflower Pharmaceutical stock can currently be bought for about CNY 11.43 on popular exchanges. Current supply of Sunflower Pharmaceutical stocks is 583.6 mn. Sunflower Pharmaceutical has a current market capitalization of CNY 6.6 bn and approximately CNY 47.8 mn worth of Sunflower Pharmaceutical was traded on exchanges in the last 24 hours. Since last month end, Sunflower Pharmaceutical has traded 0 % flat. Simple moving average of last 200 days is at CNY 12.4. The highest price of past 52 weeks was recorded at CNY 15.42 on 12/11/2025. 52 weeks low was at CNY 10.95 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Zhejiang Wanliyang (002434.SZ) traded flat 0 % and now trades at CNY 6.06. Current market capitalisation for Zhejiang Wanliyang is CNY 7.9 bn. Zhejiang Wanliyang has a current price to earnings ratio of 243.09.

  • Hunan Valin Wire & Cable (001208.SZ) traded flat 0 % and now trades at CNY 12.13. Current market capitalisation for Hunan Valin Wire & Cable is CNY 7.9 bn. Current price/earnings ratio for Hunan Valin Wire & Cable is 81.41.

  • Heilongjiang Tianyouwei Electronics (603202.SS) traded flat 0 % and now trades at CNY 49.37. Current market capitalisation for Heilongjiang Tianyouwei Electronics is CNY 7.8 bn.

  • Hna (600751.SS) traded flat 0 % and now trades at CNY 2.71. Current market capitalisation for Hna is CNY 1.1 bn. Current price/earnings ratio for Hna is 103.08.

  • Zhuhai Aerospace Microchip (300053.SZ) traded flat 0 % and now trades at CNY 11.05. Zhuhai Aerospace Microchip has a market capitalisation of CNY 7.9 bn. ZHUHAI AEROSPACE MICROCHIP reported a positive outlook for the upcoming quarter, citing improved performance across its semiconductor and aerospace segments. The company highlighted continued growth in the global semiconductor market, noting that it had secured increased demand from key clients and expanded product certifications. It also referenced accelerated investment in artificial‑intelligence infrastructure and data‑center construction, which has spurred sales in that area. Internally, the firm emphasized enhanced operational efficiency and cost management, attributing higher profitability to streamlined production and refined supply‑chain controls. While specific figures were not disclosed, the company expects its revenue and net income for the first three quarters of 2026 to rise, reflecting the broader momentum in the high‑technology and aerospace sectors.

About Sunflower Pharmaceutical

The Sunflower Pharmaceutical Group Co., Ltd. is a health care sector company based in Harbin, China. The company specializes in conducting research, developing, packaging, and marketing pharmaceutical drugs. These products are intended for distribution to the pharmaceutical and medical industries. You can find more information about their offerings on their website, www.kuihuayaoye.com , and they are listed on the Shenzhen Stock Exchange.